|
KMID : 1100720190390010086
|
|
Annals of Laboratory Medicine
2019 Volume.39 No. 1 p.86 ~ p.90
|
|
|
Performance Evaluation of the Beckman Coulter DxN VERIS Hepatitis B Virus (HBV) Assay in Comparison With the Abbott RealTime HBV Assay
|
|
Park Joon-Hong
Cho Han-Wool
Choi Seung-Jun
Lee Gun-Dong
Sin Sang-Hyun
Ryu Ji-Hyeong
Park Hye-Sun
Lee Hye-Young
Kim Yong-Goo
Oh Eun-Jee
|
|
|
Abstract
|
|
|
|
The detection and quantification of hepatitis B virus (HBV) DNA plays an important role in diagnosing and monitoring HBV infection as well as in assessing the therapeutic response. We compared the analytical performance of a random access, fully automated HBV assay?DxN VERIS Molecular Diagnostics System (Beckman Coulter, Brea, CA, USA)?with that of Abbott RealTime HBV assay (Abbott Laboratories, Des Plaines, IL, USA). The between-day precision of the VERIS assay ranged from 0.92% (mean 4.68 log IU/mL) to 4.15% (mean 2.09 log IU/mL) for pooled sera from HBV patients. HBV DNA levels measured by the VERIS HBV assay correlated with the calculated HBV DNA levels (r2=0.9994; P<0.0001). The lower limit of quantification was estimated as 8.76 IU/mL (Probit analysis, 95% confidence interval: 7.32?12.00 IU/mL). Passing-Bablok regression analysis showed good concordance between the VERIS and RealTime assays for 187 chronic HBV samples (y=?0.2397+0.9712x; r=0.981), as well as for 20 drug-resistant HBV genotype C positive samples (y=?0.5415+0.9954x; r=0.961). The VERIS assay demonstrated performance similar to the RealTime assay and is suitable for high-throughput HBV DNA monitoring in large hospital laboratories.
|
|
|
KEYWORD
|
|
|
Analytical performance, HBV DNA monitoring, Beckman Coulter DxN VERIS HBV assay, Abbott RealTime HBV assay
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|